Thermo Fisher Scientific Inc (TMO)
543.38
-2.89 (-0.53%)
USD |
NYSE |
Oct 06, 10:16
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 212.89B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -4.28% |
| Valuation | |
| PE Ratio | 28.92 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.022 |
| Price to Book Value | 5.034 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.30 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7155 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 24.87% |
News
Headline
Wire
Time (ET)
Yahoo
10/05 10:01
Yahoo
10/04 08:00
SA Breaking News
10/03 06:14
Yahoo
10/01 09:00
MT Newswires
09/29 08:25
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/27/2022* | -- | Results | Q3 2022 | -- | 4.82 | -- | |
| 10/27/2022* | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/28/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 07/28/2022 | -- | Results | Q2 2022 | 5.51 | 4.98 | 10.61% | |
| 04/28/2022 | -- | Results | Q1 2022 | 7.25 | 6.21 | 16.80% | |
| 04/28/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/02/2022 | -- | Results | Q4 2021 | 6.54 | 5.27 | 24.01% | |
| 02/02/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2022 (revenue figures include some cross-segment revenue): analytical technologies (15% of sales); specialty diagnostic products (10%); life science solutions (30%); and lab products and services, which includes CRO services (51%). |
| URL | https://corporate.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 27, 2022 (est.) |
| Last Earnings Release | Jul. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 14, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 1.12 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.1446 |
| Yield to Sector | 0.1151 |
| Yield to Industry | 0.5354 |
| Last Dividend Amt. | 0.30 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Sep. 14, 2022 |
| Yield (TTM) | 0.21% |
| Forward Yield | 0.22% |
| Payout Ratio | 5.71% |
| Cash Payout Ratio | 6.71% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 05, 2022.
Fundamentals
| Revenue (TTM) | 42.82B |
| Total Expenses (TTM) | 33.09B |
| Net Income (TTM) | 7.439B |
| Total Assets (Quarterly) | 90.58B |
| Total Liabilities (Quarterly) | 48.11B |
| Shareholders Equity (Quarterly) | 42.29B |
| Cash from Operations (TTM) | 8.837B |
| Cash from Investing (TTM) | -20.40B |
| Cash from Financing (TTM) | 6.457B |
Ratings
Profile
Edit
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2022 (revenue figures include some cross-segment revenue): analytical technologies (15% of sales); specialty diagnostic products (10%); life science solutions (30%); and lab products and services, which includes CRO services (51%). |
| URL | https://corporate.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 27, 2022 (est.) |
| Last Earnings Release | Jul. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 14, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| IHI | 1.039B USD | 17.66% |
| FSMEX | 1.197B USD | 15.74% |
| XLV | 1.661B USD | 4.44% |
| VHT | 724.82M USD | 3.90% |
| PACLX | 1.341B USD | 2.94% |
| CAFFX | 1.537B USD | 2.34% |
| VPMCX | 1.247B USD | 2.08% |
| CGFFX | 2.789B USD | 1.38% |
| IVW | 374.47M USD | 1.37% |
| VIGRX | 1.749B USD | 1.20% |
| VUG | 1.749B USD | 1.20% |
| IWD | 512.31M USD | 1.05% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| TMO Tweets |